Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $5.2552W HIGH $11.33
Volume
124.28 K
Value Traded
12.86 M
Short % Float
4.66%
+12.22%Week
+32.17%1 Month
+22.18%3 Month
+74.19%6 Month
+73.88%5 Year
-60.7%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.86 B
EPS (TTM)
-0.15
P/E Ratio
-
Ent. Value
2.05 B
Total Shares
182.32 M
Float Shares
173.10 M
Insiders
5.05%
Institutions
59.65%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
XERS Catalyst Timeline
Dated clinical, regulatory and corporate events for Xeris Biopharma Holdings, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Xeris Biopharma Holdings, Inc.
165Total events
9Upcoming
25Tier-1 (high impact)
2019 to 2040Coverage
Upcoming catalysts 2
Event history 50
●Equity OfferingCorporate
Inducement grants of stock options and RSUs for 352,170 shares to 60 new employees
▲Patent GrantedXP-8121IP / Competition
USPTO grants U.S. Patent No. 12,691,089 for XP-8121
hypothyroidismsource ↗
▲Debt Royalty FinancingCorporate
Private exchange of $23M convertible notes for cash and stock
▲Patent GrantedKeveyisApprovedIP / Competition
USPTO issues Notice of Allowance for new Keveyis patent
primary periodic paralysissource ↗
◆Oral PresentationPresentation
Jefferies Global Healthcare Conference participation and fireside chat
●Oral PresentationPresentation
Barclays 28th Annual Global Healthcare Conference participation
◆Hatch Waxman LitigationRecorlevApprovedIP / Competition
Patent infringement lawsuit filed against Torrent and Somerset for Recorlev
endogenous Cushing's syndromesource ↗
◆Para Iv CertificationRecorlevApprovedIP / Competition
Paragraph IV Certification Notice Letters received from ANDA filers
endogenous Cushing's syndromesource ↗
●Oral PresentationPresentation
Piper Sandler 37th Annual Healthcare Conference 1x1 meetings and fireside chat
▲Patent GrantedXP-8121IP / Competition
USPTO issued Notice of Allowance for XP-8121 patent application
hypothyroidismsource ↗
▲Timing GuidanceXP-8121Presentation
XP-8121 described as Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism
hypothyroidismsource ↗
◆Oral PresentationPresentation
1x1 meetings at Craig-Hallum Institutional Investor Conference
▲Quarterly UpdateCorporate
Record first quarter 2025 financial results: total revenue $60.1M, up 48% YoY
◆Management ChangeCorporate
Kenneth Johnson to retire as SVP Global Development Medical Affairs
◆Quarterly UpdateXP-8121Corporate
XP-8121 described as Phase 3-ready once-weekly subcutaneous injection for hypothyroidism
hypothyroidismsource ↗
▲Milestone PaymentCorporate
Received approval-based milestone from partner American Regent for Gvoke VialDx
▲Quarterly UpdateRecorlevApprovedCorporate
Recorlev Q4 2024 net revenue $22.6M, up 131% vs Q4 2023
endogenous Cushing's syndromesource ↗
▲Quarterly UpdateGvokeApprovedCorporate
Gvoke Q4 2024 net revenue $23.3M, up 25% vs Q4 2023
severe hypoglycemiasource ↗
▼Quarterly UpdateKeveyisApprovedCorporate
Keveyis Q4 2024 net revenue $11.1M, down 21% vs Q4 2023
primary periodic paralysissource ↗
▲Quarterly UpdateCorporate
Q3 2024 financial results: record total revenue $54.3M, product revenue $52.9M
▲Quarterly UpdateGvokeApprovedCorporate
Gvoke Q3 2024 net revenue $22.9M, up 29% YoY; prescriptions topped 70,000
severe hypoglycemiasource ↗
▲Quarterly UpdateRecorlevApprovedCorporate
Recorlev Q3 2024 net revenue $17.7M, up 119% YoY; patients on therapy up 125%
endogenous Cushing's syndromesource ↗
▼Quarterly UpdateKeveyisApprovedCorporate
Keveyis Q3 2024 net revenue $12.2M, down 23% YoY
primary periodic paralysissource ↗
Past FDA Catalysts and PDUFA Decisions
How XERS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-03-14 | Gvoke Kit (glucagon) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C50 / 100
Pipeline Score
$501M
Pipeline Value
$778M
Commercial Value
Overvalued
Valuation Signal
1
Drugs Scored
0.6x
rNPV / MCap
Top 18%
Micro Cap(rank 119 of 658)
Percentile Rank
Xeris Biopharma Holdings, Inc. carries a moderate pipeline score (50/100), with $2.5B risk-adjusted pipeline value, led by PRAM9 in Diabetes Mellitus, Type 1 (Phase 2), across $101B in total addressable markets.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $335.4M x 2.3 = $778M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Recorlev | $189M | $97M | +94.1% |
| Gvoke | $93M | $91M | +2.9% |
| Keveyis | $48M | $46M | +4.5% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PRAM9 Small moleculeCompletedNCT04074317 | Diabetes Mellitus, Type 1 | Phase 2 | COMPLETED | 18 | Apr 2, 2020 |
Clinical Trial Results
Readouts, endpoints and source filings for every XERS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| XP-8121 | hypothyroidism | Phase 1 | 2022-10-20 | 600 g, 1200 g, and 1500 g of XP-8121; dose conversion factor of 4X; 100 million prescriptions per year; exposure from weekly XP-8121 1200 g SC doses overlaps daily Synthroid PO 300 gRead More | XERIS BIOPHARMA ANNOUNCES POSITIVE TOPLINE PHASE 1 CLINICAL DATA OF ITS INVESTIGATIONAL SUBCUTANEOUS (SC) LEVOTHYROXINE (XP-8121) HOSTS CONFERENCE CALL AND WEBCAST Data demonstrate proof-of-concept showing a once weekly Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Hecht BethOfficer (See Remarks) | Sell | -16,666 1,111,130 held | $9.41 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in XERS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 1.5 % (50 %) | 14.32 M | 1.81 M | 5.02% ( 86.36 K) |
XERS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How XERS ranks across every disease it competes in
Competitive Position is a premium feature
See how XERS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialXERS News
XERS▲ +11.6%on this news
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Biopharma Holdings announced the grant of stock options and restricted stock units to 60 new employees under its Inducement Equity Plan. This initiative aims to attract talent as the company continues to grow and develop innovative therapies. The stock options have a ten-year term and vest over three years.
Read more →XERS▼ -9.1%on this news
Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism
Xeris Biopharma Holdings is hosting a webinar to discuss its XP-8121 program, which includes a detailed overview of its Phase 3 registrational study design. The investigational drug is a once-weekly subcutaneous levothyroxine for hypothyroidism. The event will also cover the commercial opportunities associated with XP-8121.
Read more →XERSXeris Announces Details for XP-8121 Program Overview Webinar
Xeris Biopharma Holdings, Inc. has announced a webinar to discuss XP-8121, their Phase 3-ready subcutaneous levothyroxine injection for hypothyroidism. The webinar is scheduled for September and aims to provide comprehensive information about the program. This initiative reflects Xeris's commitment to innovative therapies.
Read more →XERS▼ -9.2%on this news
Xeris Biopharma Reports Second Quarter 2026 Financial Results
Xeris Biopharma Holdings, Inc. reported its financial results for Q2 2026, highlighting a 34% increase in net product revenue compared to the previous year. The growth was primarily attributed to the strong commercial performance of Recorlev. This positive trend reflects the company's commitment to developing innovative therapies.
Read more →XERSXeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026
Xeris Biopharma Holdings, Inc. has announced the release of its second quarter 2026 financial results, scheduled for August 6, 2026. The results will be made public before the U.S. markets open, followed by a conference call and webcast at 8:30 a.m. Eastern Time. This event highlights the company's commitment to transparency and investor communication.
Read more →XERSCORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Xeris has announced inducement grants in accordance with Nasdaq Listing Rule 5635(C)(4). The announcement aims to clarify previous communications regarding these grants. Further details on the grants and their implications for the company were not disclosed in the article.
Read more →XERSXeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Xeris has announced inducement grants in accordance with Nasdaq Listing Rule 5635(C)(4). This rule allows companies to issue stock options to new employees as an incentive. The specifics of the grants and their potential impact on the company were not detailed in the announcement.
Read more →XERSXeris Announces Updates to Its Board of Directors
Xeris Biopharma Holdings, Inc. has announced significant updates to its Board of Directors. CEO John Shannon will take on the role of Chair of the Board, while Marla Persky transitions to Lead Independent Director. Additionally, Nerissa Kreher, M.D. has been appointed to the board, effective July 1, 2026.
Read more →XERSXeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®
Xeris Biopharma has announced that it received a notice of allowance from the U.S. Patent and Trademark Office for a new patent covering KEVEYIS®. This patent is expected to strengthen the company's intellectual property portfolio and could enhance its competitive edge in the market.
Read more →XERSXeris Biopharma Announces Private Exchange of Convertible Notes
Xeris Biopharma has announced a private exchange of convertible notes. The details regarding the terms of the exchange and its implications for the company are not specified in the article. This move may impact the company's financial strategy moving forward, but further information is needed for a comprehensive analysis.
Read more →XERSXERIS BIOPHARMA ANNOUNCES PRIVATE EXCHANGE OF CONVERTIBLE NOTES
Xeris Biopharma Holdings, Inc. has announced a private exchange of its 8.00% Convertible Senior Notes due in 2028, eliminating approximately $23 million in debt and achieving nearly $2 million in annual interest savings. This transaction involves the exchange of cash and common stock based on the average price over a designated trading period. After the exchange, the total outstanding amount of the Notes will be $10.5 million. The company continues to advance its development pipeline, which includes therapies for various health conditions.
Read more →XERSXERIS BIOPHARMA REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
Xeris Biopharma Holdings, Inc. reported strong financial results for the first quarter of 2026, showcasing a 43% increase in total product revenue to over $82 million. The standout performer, Recorlev, achieved a remarkable 95% growth in net revenue, amounting to $50 million. Xeris has also updated its revenue guidance for the full year to between $380 million and $390 million, reflecting anticipated continued growth. However, Gvoke's revenue showed no growth year-on-year, and R&D expenses saw a notable rise, indicating some operational challenges.
Read more →XERSXeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026
Xeris Biopharma Holdings, Inc. will announce its first quarter 2026 financial results on May 7, 2026, before U.S. markets open. A conference call and webcast will follow at 8:30 a.m. ET to discuss the results. The company is known for its innovative therapies, including products for Cushing's syndrome and severe hypoglycemia.
Read more →XERSXeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance
Xeris Biopharma reported record financial results for Q4 and full year 2025, highlighting significant revenue growth and a positive outlook for 2026. The company anticipates total revenue between $375 million and $390 million, driven by strong demand for its products. However, challenges include a decline in Keveyis revenue and rising operational costs.
Read more →XERSXERIS BIOPHARMA SUBSIDIARIES FILE RECORLEV PATENT INFRINGEMENT LAWSUIT
Xeris Biopharma Holdings has filed a patent infringement lawsuit against Torrent Pharmaceuticals and Somerset Therapeutics over their attempts to introduce a generic version of Recorlev. The lawsuit, which was submitted to the U.S. District Court for New Jersey, aims to prevent the production and sale of generic levoketoconazole until Xeris's patents expire in March 2040. Xeris expressed confidence in its patent strategy as it seeks to protect its intellectual property and market position. The filing follows receipt of Paragraph IV Certification Notice Letters from the ANDA filers claiming the patents are invalid or will not be infringed.
Read more →XERSXeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026
Xeris Biopharma Holdings, Inc. will report its fourth quarter and full year 2025 financial results on March 2, 2026. The company will also provide guidance for the full year 2026 during a conference call scheduled for 8:30 a.m. Eastern Time. Interested parties can pre-register for the call and access a replay afterward.
Read more →XERSXeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Biopharma Holdings announced the grant of 181,550 restricted stock units to 50 new employees under its Inducement Equity Plan. This plan is designed to attract individuals not previously employed by Xeris as part of their employment offer. The stock units will vest over three years, contingent on continued employment. Xeris is committed to developing innovative therapies and has a robust pipeline.
Read more →XERSXeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application
Xeris Biopharma Holdings has received a Notice of Allowance from the USPTO for its XP-8121 patent application. This approval highlights the patentability of XP-8121, a novel formulation designed for hypothyroidism treatment via subcutaneous injection. The company aims to enhance its intellectual property protections while addressing significant medical needs in this area.
Read more →XERS▼ -21.9%on this news
XERIS BIOPHARMA POSTS RECORD FINANCIAL RESULTS FOR THE THIRD QUARTER 2025
Xeris Biopharma reported strong financial results for Q3 2025, with total product revenue reaching $74 million, up 40% year-over-year. The company highlighted a remarkable 109% growth in Recorlev revenue, which represents a significant increase in patient demand. Additionally, Xeris updated its full-year guidance to $285-$290 million, underscoring its ongoing growth trajectory. While Keveyis experienced a slight revenue decline, the overall performance indicates a solid recovery as evidenced by a reported net income compared to a loss in the previous year.
Read more →About Xeris Biopharma Holdings, Inc.
Headquarters1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL, 60607
BIOPHARMAWATCH ELITE PLUS
Trade the next XERS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime